Evidence map›Paper›PMID 39160548›Full record

ReviewCell communication and signaling : CCS2024

SUMOylation at the crossroads of gut health: insights into physiology and pathology.

Xue-Ni Ma, Mu-Yang Li, Guo-Qing Qi, Li-Na Wei, De-Kui Zhang

Abstract readReview
In one paragraph

Review in Cell communication and signaling : CCS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. UBE2L6 drives ulcerative colitis progression by promoting BIRC2 degradation and activating non-canonical NF-κB signalling.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xue-Ni MaKey Laboratory of Digestive Diseases, Lanzhou University Second Hospital, Lanzhou, 730030, China.
Mu-Yang LiKey Laboratory of Digestive Diseases, Lanzhou University Second Hospital, Lanzhou, 730030, China.
Guo-Qing QiDepartment of Gastroenterology, Lanzhou University Second Hospital, Lanzhou, 730030, China.
Li-Na WeiDepartment of Gastroenterology, Lanzhou University Second Hospital, Lanzhou, 730030, China.
De-Kui ZhangKey Laboratory of Digestive Diseases, Lanzhou University Second Hospital, Lanzhou, 730030, China. zhangdk8616@126.com.

Funding

Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital CY2021-QN-B14Education Science and Technology Innovation Project of Gansu Province 2022B-061Natural Science Foundation of Gansu Province 22JR11RA066
6 · The paper itself

Abstract

SUMOylation, a post-translational modification involving the covalent attachment of small ubiquitin-like modifier (SUMO) proteins to target substrates, plays a pivotal role at the intersection of gut health and disease, influencing various aspects of intestinal physiology and pathology. This review provides a comprehensive examination of SUMOylation's diverse roles within the gut microenvironment. We examine its critical roles in maintaining epithelial barrier integrity, regulating immune responses, and mediating host-microbe interactions, thereby highlighting the complex molecular mechanisms that underpin gut homeostasis. Furthermore, we explore the impact of SUMOylation dysregulation in various intestinal disorders, including inflammatory bowel diseases and colorectal cancer, highlighting its implications as a potential diagnostic biomarker and therapeutic target. By integrating current research findings, this review offers valuable insights into the dynamic interplay between SUMOylation and gut health, paving the way for novel therapeutic strategies aimed at restoring intestinal equilibrium and combating associated pathologies.

Indexed as

SumoylationAnimalsHumansInflammatory Bowel DiseasesColorectal cancerGutInflammatory bowel diseasesPathologyPhysiologySUMOylation

Identifiers

PMID39160548
PMCPMC11331756

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.